title: [Three patients with primary AL amyloidosis treated by high-dose melphalan with autologous peripheral blood stem cell transplantation].
abstract: We present three long-term survivors treated with high-dose melphalan with autologous peripheral blood stem cell transplantation(auto PBSCT)for primary AL amyloidosis. Because melphalan toxicity is dose-related, patient age and the extent of organ involvement are very important factors for the success of high-dose melphalan treatment with PBSCT. The patients were therefore given high-dose melphalan using the risk-adapted approach to melphalan dosing. They received 3 courses of a vincristine, doxorubicin and dexamethasone(VAD)regimen, along with high-dose melphalan(100-200mg/m2)with auto PBSCT. There were no serious complications or transplantation-related mortalities. Patients survived for an average of 68 months(22-100 months)in partial response. A risk-adapted approach to melphalan dosing with PBSCT is an effective treatment in patients with primary AL amyloidosis.
authors.affiliation: Dept. of Hematology, Osaka City General Hospital.
authors.forename: Satoru
authors.initials: S
authors.lastname: Mukai
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kanashima
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Ogawa
authors.forename: Takafumi
authors.initials: T
authors.lastname: Nakao
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Teshima
authors.forename: Takahisa
authors.initials: T
authors.lastname: Yamane
mesh_terms: D000686:Amyloidosis / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D001706:Biopsy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D000075363:Immunoglobulin Light-chain Amyloidosis; D008297:Male; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation
chemical_list: D008558:Melphalan